BEHIND BOTANICAL DRUGS

THE EXPERTISE YOU CAN TRUST

INTRODUCING NUVASTATIC™ - THE ANGIOGENESIS INHIBITOR BACKED BY EMAN RESEARCH

A trusted leader in Botanical Drugs with 10 years of experience in oncology


NUVASTATIC™ will be indicated for the treatment of:

  • Metastatic colorectal cancer(mCRC)
  • Metastatic breast cancer(mBC)
  • Cancer aesthenia
  • Cancer in induced anxiety
  • Immuno system booster palliative care

THE FIRST BOTANICAL DRUG
MANUFACTURER IN ONCOLOGY

TGA approved safe, medicinally effective angiogenesis inhibitor





Comprehensive support for you and your patients







NATURECEUTICALS HAS ACHIEVED

LARGE

PRODUCTION CAPACITY ENABLES TO FULFILL SIGNIFICANT

MARKET DEMAND





BACKED BY
EMAN RESEARCH EXPERTISE

10

YEARS

experience in oncology





About Us

NatureCeuticals is established based on research collaboration between top Australian and Malaysian universities. We aspire to transform medicinal herbs into main stream pharmaceuticals that are safe and effective. We go to great lengths to achieve what is thought to be impossible for herbs by introducing ground breaking technologies that helps to catapult herbs into pharmaceuticals.

Our Technologies

Our proprietary state-of-the-art manufacturing and formulation technologies help to improve the potency of our herbal products. These help to increase the amount of vital plant nutrients and enhance their absorption making our herbal products far more effective than their natural form.

Research

We conduct clinical and preclinical studies on our products to validate their safety and effectiveness. Our commitment to continuously improve herbal pharmaceuticals has led us to establish our very own not-for-profit research institute to advance our scientific endeavour . We also support various university research projects to help to deepen our knowledge and understanding in modern herbal medicine.


NATURECEUTICALS FEATURED NEWS




RECENT NEWS


8/2/2019

NatureCeuticals Announces 2019 Third Quarter Dividend

7/30/2019

NatureCeuticals Reports Second Quarter 2019 Financial Results

7/26/2019

NatureCeuticals Controls 98% of The Shares In Nuevolution After The End Of The Extended Acceptance Period



IN THIS SECTION

Interested? please learn
more and buy now.

Order now

want tools,tips and
product support?

Sign Up
Facebook Email